Meeting
2023 ASCO Annual Meeting
MagnetisMM-7: An open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly diagnosed multiple myeloma.
Authors
Maria Victoria Mateos Manteca
Salamanca University Hospital, Salamanca, Spain
Maria Victoria Mateos Manteca , Sebastian Grosicki , Kihyun Kim , Eric Negre , Erik Vandendries
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT05317416
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS8066)
DOI
10.1200/JCO.2023.41.16_suppl.TPS8066
Abstract #
TPS8066
Poster Bd #
56b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM).
First Author: Sebastian Grosicki
Poster
2022 ASCO Annual Meeting
MagnetisMM-5: An open-label, multicenter, randomized phase 3 study of elranatamab as monotherapy and in combination with daratumumab in patients with relapsed/refractory multiple myeloma.
First Author: Sebastian Grosicki
First Author: Nina Shah
Poster
2021 ASCO Annual Meeting
ECOG-ACRIN EAA181: Effective quadruplet utilization after treatment evaluation (EQUATE)—a randomized phase 3 trial for newly diagnosed multiple myeloma (NDMM) not intended for early autologous transplantation.
First Author: Shaji Kumar